ReviewJMA journal2026
Impact of the 2018 Japan Floods on Methotrexate and Antirheumatic Drug Prescriptions: A Longitudinal Analysis of the Japanese National Database.
Review in JMA journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Most rheumatic diseases are caused by a complex interplay of genetic, physical, and environmental factors. Large-scale disasters affect all of these factors; however, their impact on rheumatic diseases is unknown. We aimed to investigate changes in antirheumatic drug prescriptions among victims and non-victims after the 2018 Japan Flood: the second largest water-related disaster in Japan. Methods: In this retrospective cohort study, we used data from the Japanese National Database of Health Insurance Claims, which included information on all drugs prescribed by physicians. We included all cases of prescription at medical institutions in disaster-stricken areas between July 2017 and June 2019. The newly initiated prescription of methotrexate (MTX, 2-mg tablets or capsules), which has been exclusively approved for rheumatoid arthritis, juvenile idiopathic arthritis, or psoriatic arthritis/psoriasis in Japan, and other antirheumatic drugs within the first year after the disaster were evaluated for government-certified disaster victims and non-victims. Baseline characteristics and MTX prescription status in the pre-disaster period were also assessed to compare the groups. Results: In the pre-disaster period, no significant association was found between victim status and MTX prescription. The number of individuals who had not been prescribed MTX before the disaster was 4,973,401, including 31,006 victims. Among them, 14,908 (including 110 victims) had a history of MTX prescription after the disaster. In the MTX-naive group, new MTX prescriptions within one year after the disaster were significantly more frequent in victims than in non-victims (age- and sex-adjusted hazard ratio: 1.83; 95% confidence interval: 1.37-2.46). Similarly, a non-significant increase in prescriptions for conventional synthetic/biological disease-modifying antirheumatic drugs was observed. Conclusions: Victims of the 2018 Japan Flood were more likely to be prescribed MTX for the first time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.